Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Building a balanced search formula for pharmacovigilance and literature monitoring

Posted on March 21st, 2017 by in Pharmacovigilance

Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. Continue reading “Building a balanced search formula for pharmacovigilance and literature monitoring” »

The New Clinical Trial Directive, Low Risk Intervention Clinical Trials and Pharmacovigilance Reporting Adjustments

Posted on October 3rd, 2016 by in Pharmacovigilance

The new Clinical Trial Directive (EU 536/2014), is applicable since May 2016 with a transition period of three years (May 2019) for CT applications submitted before that date. Continue reading “The New Clinical Trial Directive, Low Risk Intervention Clinical Trials and Pharmacovigilance Reporting Adjustments” »